Given the unmet clinical need for accurately staging and restaging prostate cancer as well as detecting sites of biochemical recurrence and lack of industry support, we initiated a pivotal phase 3 clinical trial for 68Ga-PSMA-11 to study its efficacy and safety in prostate cancer detection. The gene discussed is FOLH1; the disease is Familial prostate cancer.